Johnson & Johnson forecasts 2026 sales and profit above Wall Street estimates, despite “hundreds of millions of dollars” impact from drug pricing deal with Trump admin. J&J expects operational sales of $99.5B to $100.5B and profit of $11.43 to $11.63 per share in 2026. Shares fell 2.7% in premarket trading.

Court-appointed special master recommends expert testimony linking J&J’s talc products to ovarian cancer. J&J disputes claims, saying products are safe. Q4 2025 profit beats expectations, driven by strong sales of Darzalex and Tremfya. Challenges include tariff uncertainty and competition for psoriasis drug Stelara.

Despite Stelara sales decline, J&J reports overall growth in portfolio. On an adjusted basis, Q4 earnings were $2.46 per share, beating analyst expectations of $2.44. Quarterly revenue of $24.56B surpasses Wall Street’s forecast of $24.16B. Company remains optimistic about future growth and performance.

Read more at Yahoo Finance: Johnson & Johnson forecasts 2026 profit above Wall Street estimates